Loading...
Market
What will be VK2735's market share in obesity drugs by end of 2025?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Market analysis reports from research firms like IMS Health or EvaluatePharma
Story
Viking Therapeutics' Obesity Drug Shows 8.2% Weight Loss, Strong Safety Profile
Nov 4, 2024, 01:44 AM
Viking Therapeutics ($VKTX) has reported promising results from its Phase 1 trial of the oral obesity drug VK2735. The drug demonstrated an 8.2% weight loss in patients, positioning it as a strong competitor against market leaders like Novo Nordisk ($NVO) and Eli Lilly ($LLY). The trial also highlighted the drug's excellent safety profile, showing similar gastrointestinal tolerability to placebo across all dose escalations up to 100mg. The study observed no moderate or severe nausea and only one case of vomiting, even at higher doses. Additionally, a 28-day study showed a 5.3% reduction from baseline with no discontinuations. These results have generated significant anticipation in the market, with analysts suggesting that VK2735 could potentially reach triple-digit stock prices. The total addressable market (TAM) for obesity treatments is estimated to be over $200 billion, while Viking Therapeutics' market cap is currently around $10 billion.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Approved • 25%
Conditionally approved • 25%
Not approved • 25%
Approval pending • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%